(Q34774483)

4 August 2017

1 reference

title

DHEA treatment: myth or reality? (English)

1 reference

4 August 2017

2

Wiebke Arlt

1 reference

4 August 2017

1

Bruno Allolio

1 reference

4 August 2017

1 September 2002

1 reference

Trends in Endocrinology and Metabolism

4 August 2017

1 reference

4 August 2017

13

1 reference

4 August 2017

7

1 reference

4 August 2017

288-294

1 reference

Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations throughout Adulthood

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Hormonal changes in puberty III: Correlation of plasma dehydroepiandrosterone, testosterone, FSH, and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison's disease or hypogonadism or with premature or late ad

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Secretion of the adrenal androgen, dehydroepiandrosterone sulfate, during normal infancy, childhood, and adolescence, in sick infants, and in children with endocrinologic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The actions of exogenous dehydroepiandrosterone in experimental animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Oral Dehydroepiandrosterone for Adrenal Androgen Replacement: Pharmacokinetics and Peripheral Conversion to Androgens and Estrogens in Young Healthy Females after Dexamethasone Suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

1 reference

7 January 2021

Origin of plasma androstanediol glucuronide in men

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Precursors of plasma androstanediol- and androgen-glucuronides in women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Characterization and measurement of dehydroepiandrosterone sulfate in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3).

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dissociation of adrenal androgen and cortisol levels in acute stress.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Androgen deficiency in women.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Quality of life in patients with Addison's disease: effects of different cortisol replacement modes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Decreased psychological well-being in adult patients with growth hormone deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone replacement in women with adrenal insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone replacement in addison's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone for adrenal insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone replacement for patients with adrenal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone treatment of midlife dysthymia.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Effects of DHEA replacement on bone mineral density and body composition in elderly women and men

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Replacement of DHEA in aging men and women. Potential remedial effects

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Activation of human monocytes by LPS and DHEA

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Preliminary studies on the effect of dehydroepiandrosterone (DHEA) on both constitutive and phytohaemagglutinin (PHA)-inducible IL-6 and IL-2 mRNA expression and cytokine production in human spleen mononuclear cell suspensions in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900617-3

7 January 2021

10.1016/S1043-2760(02)00617-3

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12163230